Skip to main content
Log in

Therapiesteuerung bei CRPC mit der Splicevariante 7 (AR-V7) des Androgenrezeptors

AR-V7 scheint prädiktiv für Resistenz gegen antiandrogene Therapie

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Hu R et al. Cancer Res. 2009;69(1):16–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Ryan CJ et al. N Engl J Med. 2013;368(2):138–148.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Beer TM et al. N Engl J Med. 2014;371(5):424–433.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Scher HI et al. N Engl J Med. 2012;367(13):1187–1197.

    Article  CAS  PubMed  Google Scholar 

  5. Ryan CJ et al. Lancet Oncol. 2015 Feb;16(2):152–160.

    Article  CAS  PubMed  Google Scholar 

  6. Azad AA et al. Clin Cancer Res. 2015;21(10):2315–2324.

    Article  CAS  PubMed  Google Scholar 

Originalie

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Winfried Alsdorf.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alsdorf, W., Bokemeyer, C. AR-V7 scheint prädiktiv für Resistenz gegen antiandrogene Therapie. Info Onkol. 18, 14–16 (2015). https://doi.org/10.1007/s15004-015-0933-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-0933-3

Schlüsselwörter

Navigation